Top

Published in:

01-06-2007 | Commentary

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?

Authors: Vladislava Simkova, Peter Radermacher, Eberhard Barth

Published in: Critical Care | Issue 3/2007

Abstract

Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines).

Heringlake M, Wernerus M, Gruenefeld J, Klaus S, Heinze H, Bechtel M, Bahlmann L, Poeling J, Schoen J: The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care 2007, 11: R51. 10.1186/cc5904PubMedCentralCrossRefPubMed

Leverve XM: From tissue perfusion to metabolic marker: assessing organ competition and co-operation in critically ill patients? Intensive Care Med 1999, 25: 890-892. 10.1007/s001340050976CrossRefPubMed

Vanhorebeek I, Ingels C, Van den Berghe G: Intensive insulin therapy in high-risk cardiac surgery patients: evidence from the Leuven randomized study. Semin Thorac Cardiovasc Surg 2006, 18: 309-316. 10.1053/j.semtcvs.2006.05.001CrossRefPubMed

Revelly JP, Tappy L, Martinez A, Bollmann M, Cayeux MC, Berger MM, Chiolero RL: Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med 2005, 33: 2235-2240. 10.1097/01.CCM.0000181525.99295.8FCrossRefPubMed

Okuda M: A multidisciplinary overview of cardiogenic shock. Shock 2006, 25: 557-570.PubMed

Orime Y, Shiono M, Hata H, Yagi S, Tsukamoto S, Kimura S, Ohmiya S, Sezai A, Yamada H, Obana M, Sezai Y: Post-operative effects of olprinone after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg 1998, 4: 340-346.PubMed

Siostrzonek P, Koreny M, Delle-Karth G, Haumer M, Koller-Strametz J, Heinz G: Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 2000, 44: 403-409. 10.1034/j.1399-6576.2000.440408.xCrossRefPubMed

Schricker T, Radermacher P, Träger K, Kugler B, Georgieff M: Metabolic and hemodynamic response to the phosphodiesterase-III-inhibitor enoximone in septic patients. Clin Intensive Care 1996, 7: 116-120.

Jungas RL, Halperin ML, Brosnan JT: Quantitative analysis of amino acid oxidation and related gluconeogenesis in humans. Physiol Rev 1992, 72: 419-448.PubMed

10.

Ayuso MS, Vega P, Manchon CG, Parrilla R: Interrelation between gluconeogenesis and hepatic protein synthesis. Biochim Biophys Acta 1986, 883: 33-40.CrossRefPubMed

11.

Möllhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD, Asfour B, Berendes E: Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999, 90: 72-80. 10.1097/00000542-199901000-00012CrossRefPubMed

12.

Kern H, Schröder T, Kaulfuss M, Martin M, Kox WJ, Spies CD: Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock. Crit Care Med 2001, 29: 1519-1525. 10.1097/00003246-200108000-00004CrossRefPubMed

13.

Parsonage WA, Hetmanski D, Cowley AJ: Beneficial haemodynamic effects of insulin in chronic heart failure. Heart 2001, 85: 508-513. 10.1136/heart.85.5.508PubMedCentralCrossRefPubMed

14.

Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB: Biomarkers of acute renal injury and renal failure. Shock 2006, 26: 245-253. 10.1097/01.shk.0000225415.5969694.ceCrossRefPubMed

15.

Chiu YJ, Hu SH, Reid IA: Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects. J Pharmacol Exp Ther 1999, 290: 16-19.PubMed

16.

Samikkannu T, Thomas JJ, Bhat GJ, Wittman V, Thekkumkara TJ: Acute effect of high glucose on long-term cell growth: a role for transient glucose increase in proximal tubule cell injury. Am J Physiol Renal Physiol 2006, 291: F162-F175. 10.1152/ajprenal.00189.2005CrossRefPubMed

17.

Leverve X: Hyperglycemia and oxidative stress: complex relationships with attractive prospects. Intensive Care Med 2003, 29: 511-514.PubMed

18.

Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, Radermacher P, Calzia E: Glucose metabolism and catecholamines. Crit Care Med 2007, in press.

Title: Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
Authors: Vladislava Simkova
Peter Radermacher
Eberhard Barth
Publication date: 01-06-2007
Publisher: BioMed Central
Published in: Critical Care / Issue 3/2007
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc5924

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units

The simple and the simpler in pneumonia diagnosis

Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department

Attributable mortality of Acinetobacter baumannii: no longer a controversial issue

Injurious mechanical ventilation in the normal lung causes a progressive pathologic change in dynamic alveolar mechanics

Diagnostic yield of quantitative endotracheal aspirates in patients with severe nursing home-acquired pneumonia